Eton Pharmaceuticals, Inc. (ETON)
NGM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 22.5M | 21.3M | 24.3M | 37.6M |
| Gross Profit | 7.9M | 13.1M | 14.7M | 25.4M |
| Operating Income | (1.4M) | 2.5M | 2.4M | 12.8M |
| Net Income | (1.9M) | 1.5M | 1.6M | 11.6M |
| Diluted EPS | $-0.07 | $0.05 | $0.05 | $0.35 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 21.3M | 31.6M | 39.0M | 80.0M |
| Gross Profit | 14.3M | 21.1M | 23.4M | 42.7M |
| Operating Income | (8.3M) | (1.2M) | (2.6M) | (844K) |
| Net Income | (9.0M) | (936K) | (3.8M) | (4.6M) |
| Diluted EPS | $-0.36 | $-0.04 | $-0.15 | $-0.17 |